XOMA Royalty (XOMA) EBT (2011 - 2026)
XOMA Royalty's (XOMA) quarterly EBT came in at $4.5 million in Q1 2026, up 88.68% year-on-year from $2.4 million in Q1 2025, and up 117.26% quarter-over-quarter from -$25.9 million in Q4 2025.
XOMA Royalty (XOMA) EBT (2011 - 2026) Analysis & Trends
XOMA Royalty has disclosed EBT across 16 years of filings, most recently posting $4.5 million for Q1 2026.
- EBT for Q1 2026 came in at $4.5 million, up 88.68% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.9 million (up 68.01% YoY), and the FY2025 annual result was -$217000.0, down 219.12% from the prior year.
- EBT came in at $4.5 million for Q1 2026 at XOMA Royalty, up from -$25.9 million in the prior quarter.
- In the past five years, EBT ranged from a high of $14.1 million in Q3 2025 to a low of -$25.9 million in Q4 2025.
- The 5-year median for EBT is -$5.8 million (2023), against an average of -$5.5 million.
- Across the five-year window, EBT plunged 392.49% in 2023 and jumped 181.77% in 2025, its largest moves.
- XOMA Royalty's EBT stood at -$6.2 million in 2022, then slumped by 221.0% to -$19.9 million in 2023, then jumped by 149.09% to $9.8 million in 2024, then slumped by 364.44% to -$25.9 million in 2025, then surged by 117.26% to $4.5 million in 2026.
- The last three EBT figures came in at $4.5 million (Q1 2026), -$25.9 million (Q4 2025), and $14.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -15.31 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.18 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | XOMA Royalty | 5.52 Mn | -60.57 Mn | - | 4.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.47 Mn |
| Dec 31, 2025 | -25.88 Mn |
| Sep 30, 2025 | 14.10 Mn |
| Jun 30, 2025 | 1.37 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Dec 31, 2024 | 9.79 Mn |
| Sep 30, 2024 | -17.24 Mn |
| Jun 30, 2024 | -13.48 Mn |
| Mar 31, 2024 | -10.56 Mn |
| Dec 31, 2023 | -19.93 Mn |
| Sep 30, 2023 | -5.79 Mn |
| Jun 30, 2023 | -5.96 Mn |
| Mar 31, 2023 | -10.17 Mn |
| Dec 31, 2022 | -6.21 Mn |
| Sep 30, 2022 | -4.37 Mn |
| Jun 30, 2022 | -4.77 Mn |
| Mar 31, 2022 | -2.07 Mn |
| Dec 31, 2021 | 29.95 Mn |
| Sep 30, 2021 | -4.44 Mn |
| Jun 30, 2021 | -2.24 Mn |